Apatinib for patients (pts) with advanced soft tissue sarcoma (STS) after chemotherapy: A prospective, open-label, single-arm, multicentered study.

被引：0
|
作者：
Hu, Haiyan
Yao, Yang
Fan, Zhengfu
Zhang, Hongmei
Chen, Jing
Zhang, Xing
Chen, Yong
Qu, Guofan
Huang, Gang
Zhou, Yuhong
Yu, Wenxi
Wang, Xiaowen
Zhuang, Rongyuan
机构：
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai, Peoples R China
[2] Beijing Canc Hosp, Beijing, Peoples R China
[3] Xijing Hosp, Xian, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[5] Sun Yat Sen Univ, Oncol Hosp, Guangzhou, Peoples R China
[6] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[7] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[8] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[9] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[10] Fourth Mil Med Univ, Xijing Hosp, Dept Clin Oncol, Xian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11553
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer
    Li, G.
    Zhao, Y.
    Jiang, Y.
    Yang, Q.
    Huang, A.
    Chen, Y.
    Han, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S753 - S754
  • [2] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
    Feng, J.
    Shen, B.
    Xu, J.
    Wang, Q.
    Ling, G.
    Mao, Y.
    Cai, M.
    Yang, Y.
    Mei, J.
    Han, Z.
    Wu, Y.
    Shi, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S913 - S913
  • [3] Surufatinib plus toripalimab in advanced soft tissue sarcoma (STS): Results from a multicenter, single-arm, basket study.
    Cheng, Ying
    Zhang, Xing
    Lu, Ming
    Shi, Si
    Ye, Feng
    Chen, Zhendong
    Ji, Dongmei
    Song, Lijie
    Yin, Fei
    Shi, Haiyan
    Zhou, Jinghong
    Tan, Panfeng
    Fan, Songhua
    Xu, Qian
    Shi, Michael
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 42 - 42
  • [4] Camrelizumab plus apatinib for patients with advanced mucosal melanoma: A prospective single-arm study.
    Zou, Zhengyun
    Zhao, Lianjun
    Ren, Yu
    Sha, Huizi
    Liu, Baorui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.
    Wang, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial
    Wang, Xuan
    Wu, Xiaowen
    Yang, Yue
    Xu, Weiran
    Tian, Hui
    Lian, Bin
    Chi, Zhihong
    Si, Lu
    Sheng, Xinan
    Kong, Yan
    Zhou, Li
    Mao, Lili
    Li, Siming
    Tang, Bixia
    Yan, Xieqiao
    Bai, Xue
    Guo, Jun
    Cui, ChuanLiang
    EUROPEAN JOURNAL OF CANCER, 2023, 182 : 57 - 65
  • [7] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
  • [8] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Fu, Xiaorui
    Li, Xin
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Zhang, Jieming
    Li, Zhaoming
    Zhang, Mingzhi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284
  • [9] Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study
    Wang, Jianping
    Zhang, Jian
    Gao, Jie
    Zhao, Mengmeng
    Ma, Zhenkai
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 33 (06): : 573 - 581
  • [10] Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006) a multicentre, open-label, single-arm, phase 2 trial
    Xu, Bushu
    Pan, Qiuzhong
    Pan, Hua
    Li, Haomiao
    Li, Xianan
    Chen, Jing
    Pang, Danmei
    Zhang, Baoqing
    Weng, Desheng
    Peng, Ruiqing
    Fang, Meiyu
    Zhang, Xing
    ECLINICALMEDICINE, 2023, 64
12345